Cardiology Surgery, Devices And Drugs Market
Cardiology Surgery, Devices And Drugs Market By Devices Types , By Drugs Types , By Drugs Mechanism, By Surgeries Types - Global Industry Share, Growth, Competitive Analysis And Forecast, 2018-2023
Cardiology surgery, devices, and drugs market is expected to grow at a CAGR of 7.4% for the forecasted period of 2018-2023. The report covers three major segments of the interventional cardiology market which include surgeries, devices, and drugs. As per WHO more than 17 million people died due to CVD in 2015 which makes is the number one cause of death globally. Some of the major CVDs include coronary heart diseases, stroke, hypertensive heart diseases, inflammatory heart diseases, rheumatoid heart diseases and others. Coronary heart diseases are the leading cause of death followed by strokes. The prevalence and incidence rate of heart diseases are on a rise; especially in major emerging countries such as India, China, and Japan. The Cardiology surgery devices market, devices, and drugs are also on a rise.
One of the major factors driving the market is medical tourism. Especially in emerging markets such as India, ASEAN countries and China, the cost of surgery and treatment for cardiovascular diseases is low. In India, heart surgery costs around $1,500 whereas in the United States it costs 5 to 10 times more than India. Hence, many Americans prefer to travel to India for their treatment.
North America is the leading market with the highest market share. The market is expected to grow at a CAGR of 6.8 percent. North American marker is followed by Europe, Asia-Pacific and Rest of the world. Asia Pacific market is expected to have the highest CAGR of 9.5% for the forecasted period of 2018-2023.
Key companies profiled in the report include Pfizer, Sanofi, AstraZeneca, Novartis, Bristol-Myers Squibb, Merck, Boston Scientific Corp., Medtronic, Sun Pharma, Roche Bayer, and others.
The market segmentation includes
- Cardiology Devices
- Cardiology Drugs Market by Indications
- Cardiology Drugs Market by Mechanism of Action
- Cardiology Surgeries
The report covers
- Comprehensive research methodology of global cardiology surgery, devices and drugs market.
- In-depth analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the global cardiology surgery, devices and drugs market.
- Insights about market determinants which are stimulating the global cardiology surgery, devices and drugs market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
CHAPTER 1. REPORT SUMMARY
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
CHAPTER 2. MARKET OVERVIEW AND INSIGHTS
2.1. GAP ANALYSIS
2.2. ANALYST & CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
2.2.1.1. INCREASING TREND OF MINIMALLY INVASIVE TECHNOLOGY
2.2.1.2. GROWING ANEURSYM REPAIR SURGERY MARKET
2.2.1.3. INCREASING MARKET OF ANTIDOTES DRUGS
2.2.1.4. LOW COST TREATMENT IN THE EMERGING ECONOMIES
2.2.2. RECOMMENDATION
2.2.3. CONCLUSION
2.3. REGULATIONS
2.3.1. TAX LAWS
2.3.1.1. UNITED STATES
2.3.1.2. EUROPEAN UNION
2.3.1.3. CHINA
2.3.1.4. INDIA
2.3.2. DRUGS AND DEVICE REGULATIONS
2.3.2.1. UNITED STATES
2.3.2.2. EUROPEAN UNION
2.3.2.3. CHINA
2.3.2.4. INDIA
2.3.2.5. REST OF THE WORLD
2.4. TYPE OF CARDIOVASCULAR DISEASES
2.4.1. CORONARY HEART DISEASES
2.4.2. STROKE
2.4.3. HYPERTENSIVE HEART DISEASES
2.4.4. INFLAMMATORY HEART DISEASES
2.4.5. RHEUMATIC HEART DISEASES
2.4.6. OTHER HEART DISEASES
CHAPTER 3. MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. INCREASING INCIDENCE AND PREVALENCE OF CARDIOVASCULAR DISEASES
3.1.2. MEDICAL TOURISM IN EMERGING MARKET
3.1.3. INNOVATIONS AND DEVELOPMENT OF NEW PRODUCTS
3.1.4. AVAILABILITY OF REMOTE MONITORING SOLUTIONS
3.1.5. RISING HEALTHCARE EXPENDITURE
3.2. RESTRAINTS
3.2.1. HIGH COST OF SURGERIES AND MEDICAL DEVICES IN BOTH DEVELOPED AND EMERGING MARKETS
3.2.2. STRICT GOVERNMENT POLICIES
3.3. OPPORTUNITIES
3.3.1. EMERGING MARKETS
3.3.2. GROWING HYBRID OPERATING ROOMS MARKET
CHAPTER 4. MARKET SEGMENTATION
4.1. BY CARDIOLOGY DEVICES TYPES
4.1.1. ANGIOPLASTY
4.1.2. CARDIOVASCULAR STENTS
4.1.3. CARDIOVASCULAR CATHETERS
4.1.4. CARDIAC RHYTHM MANAGEMENT
4.1.5. CARDIOVASCULAR ASSISTIVE DEVICES
4.2. BY CARDIOLOGY DRUGS TYPES
4.2.1. ANTITHROMBOTIC DRUGS
4.2.2. ANTIDYSLIPIDEMIC DRUGS
4.2.3. ANTIHYPERTENSIVE DRUGS
4.2.4. ANTI STROKE DRUGS
4.3. BY CARDIOLOGY DRUGS BY MECHANISM
4.3.1. BETA BLOCKERS
4.3.2. BETA AGONISTS
4.3.3. ALPHA BLOCKERS
4.3.4. ALPHA AGONISTS
4.3.5. SODIUM CHANNEL BLOCKERS
4.3.6. CALCIUM CHANNEL BLOCKERS
4.3.7. VASODILATORS
4.3.8. RENIN INHIBITORS
4.3.9. ANGIOTENSIN RECEPTOR BLOCKERS
4.3.10. DIURETICS
4.3.11. THROMBOLYTICS
4.4. BY CARDIOLOGY SURGERIES TYPES
4.4.1. CORONARY ARTERY BYPASS GRAFTING
4.4.2. TRANSMYOCARDIAL LASER REVASCULARIZATION
4.4.3. HEART VALVE REPAIR
4.4.4. ARRHYTHMIA TREATMENT
4.4.5. ANEURYSM REPAIR
4.4.6. HEART TRANSPLANT
CHAPTER 5. COMPETITIVE LANDSCAPE
5.1. KEY STRATEGIES
CHAPTER 6. REGIONAL ANALYSIS
6.1. NORTH AMERICA
6.1.1. UNITED STATES
6.1.2. CANADA
6.2. EUROPE
6.2.1. UNITED KINGDOM
6.2.2. FRANCE
6.2.3. GERMANY
6.2.4. ITALY
6.2.5. SPAIN
6.3. ASIA PACIFIC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. JAPAN
6.3.4. REST OF ASIA PACIFIC
6.4. REST OF THE WORLD
CHAPTER 7. COMPANY PROFILES
7.1. PFIZER
7.1.1. INTRODUCTION
7.1.2. PRODUCT PORTFOLIO
7.1.3. RECENT ACTIVITIES
7.2. SANOFI S.A.
7.2.1. INTRODUCTION
7.2.2. PRODUCT PORTFOLIO
7.2.3. RECENT ACTIVITIES
7.3. ASTRAZENECA
7.3.1. INTRODUCTION
7.3.2. PRODUCT PORTFOLIO
7.3.3. RECENT ACTIVITIES
7.4. NOVARTIS
7.4.1. INTRODUCTION
7.4.2. PRODUCT PORTFOLIO
7.4.3. RECENT ACTIVITIES
7.5. BRISTOL-MYERS SQUIBB
7.5.1. INTRODUCTION
7.5.2. PRODUCT PORTFOLIO
7.5.3. RECENT ACTIVITIES
7.6. 6. MERCK
7.6.1. INTRODUCTION
7.6.2. PRODUCT PORTFOLIO
7.6.3. RECENT ACTIVITIES
7.7. BOSTON SCIENTIFIC CORPORATION
7.7.1. INTRODUCTION
7.7.2. PRODUCT PORTFOLIO
7.8. MEDTRONIC
7.8.1. INTRODUCTION
7.8.2. PRODUCT PORTFOLIO
7.8.3. RECENT ACTIVITIES
7.9. ST. JUDE MEDICAL
7.9.1. INTRODUCTION
7.9.2. PRODUCT PORTFOLIO
7.9.3. RECENT ACTIVITIES
7.10. COOK MEDICAL
7.10.1. INTRODUCTION
7.10.2. PRODUCT PORTFOLIO
7.10.3. RECENT ACTIVITIES
7.11. CR BARD INC.
7.11.1. INTRODUCTION
7.11.2. PRODUCT PORTFOLIO
7.12. SUN PHARMA
7.12.1. INTRODUCTION
7.12.2. PRODUCT PORTFOLIO
7.12.3. RECENT ACTIVITIES
7.13. GE HEALTHCARE
7.13.1. INTRODUCTION
7.13.2. PRODUCT PORTFOLIO
7.13.3. RECENT ACTIVITIES
7.14. JOHNSON & JOHNSON
7.14.1. INTRODUCTION
7.14.2. PRODUCT PORTFOLIO
7.14.3. RECENT DEVELOPMENTS
7.15. TAKEDA PHARMACEUTICAL COMPANY LTD
7.15.1. INTRODUCTION
7.15.2. PRODUCT PORTFOLIO
7.16. DAIICHI SANKYO CO. LTD.
7.16.1. INTRODUCTION
7.16.2. PRODUCT PORTFOLIO
7.17. F. HOFFMANN-LA ROCHE LTD
7.17.1. INTRODUCTION
7.17.2. PRODUCT PORTFOLIO
7.18. BAYER AG
7.18.1. INTRODUCTION
7.18.2. PRODUCT PORTFOLIO
7.18.3. RECENT ACTIVITIES
7.19. BOEHRINGER INGELHEIM
7.19.1. INTRODUCTION
7.19.2. PRODUCT PORTFOLIO
7.20. OTSUKA
7.20.1. INTRODUCTION
7.20.2. PRODUCT PORTFOLIO
TABLE # 1 GLOBAL CARDIOLOGY DRUGS, DEVICES AND SURGERIES MARKET RESEARCH AND ANALYSIS 2017-2023 ($MILLION)
TABLE # 2 GLOBAL CARDIOLOGY MARKET, REGIONAL DISTRIBUTION, 2017-2023 ($MILLION)
TABLE # 3 KEY FACTS RELATED TO CVDS AT GLOBAL AND COUNTRY LEVEL
TABLE # 4 NEW AND INNOVATIVE PRODUCTS & TECHNOLOGIES IN INTERVENTIONAL CARDIOLOGY
TABLE # 5 COST OF HEART RELATED SURGERIES IN THE U.S., 2017
TABLE # 6 HYBRID OPERATING ROOM LABELING
TABLE # 7 GLOBAL CARDIAC RHYTHM MANAGEMENT MARKET RESEARCH AND ANALYSIS, 2017-2023 ($MILLION)
TABLE # 8 MERGER & ACQUISITIONS DURING 2015-2017
TABLE # 9 PARTNERSHIP & COLLABORATIONS DURING 2015-2017
TABLE # 10 NEW PRODUCT DEVELOPMENT AND PRODUCT APPROVALS DURING 2015-2017
TABLE # 11 OTHER ACTIVITIES DURING 2015-2017
TABLE # 12 GLOBAL CARDIOLOGY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 13 NORTH AMERICAN MARKET RESEARCH AND ANALYSIS, 2017-2023
TABLE # 14 NORTH AMERICAN MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 15 HEALTH EXPENDITURES US, 2016
TABLE # 16 STATISTICS OF CVD AND OTHER HEART DISEASES IN CANADA, 2015-2016
TABLE # 17 EUROPEAN CARDIOLOGY MARKET RESEARCH AND ANALYSIS, 2017-2023
TABLE # 18 EUROPEAN MARKET RESEARCH AND ANALYSIS, 2017-2023, ($ MILLION)
TABLE # 19 CVD STATISTICS EUROPE, 2016
TABLE # 20 STATISTICS RELATED TO CHD, CVD AND STROKE, UK
TABLE # 21 ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 22 ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 23 INDIAN CARDIOLOGY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($MILLION)
TABLE # 24 STATISTICS RELATED TO CHD, COST OF SURGERIES AND MAJOR HOSPITALS IN INDIA, 2014
TABLE # 25 CHINA CARDIOLOGY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 26 STATISTICS OF CVD, CHD, MEDICAL DEVICE IN CHINA 2014-2016
TABLE # 27 JAPAN CARDIOLOGY MARKET RESEARCH AND ANALYSIS, 2017-2023, ($MILLION)
FIGURE # 1 CARDIOLOGY DRUG MARKET BY TYPE, 2017 VS 2023 (%)
FIGURE # 2 CARDIOLOGY DRUG MARKET BY MODE OF ACTION, 2017 VS 2023 (%)
FIGURE # 3 GLOBAL CARDIOLOGY DEVICES MARKET SHARE, 2017 VS 2023 (%)
FIGURE # 4 GLOBAL CARDIOLOGY SURGERIES MARKET SHARE, 2017 VS 2023 (%)
FIGURE # 5 FATALITIES DUE TO CVD 2012 & 2030 (MILLIONS)
FIGURE # 6 CVD COST TO THE GLOBAL ECONOMY 2010 & 2030 ($ BILLIONS)
FIGURE # 7 FATALITIES FROM CORONARY ARTERY DISEASES 2012 AND 2020 (MILLIONS)
FIGURE # 8 NUMBER OF PATIENTS TRAVELLED TO INDIA 2012-2016
FIGURE # 9 ESTIMATED TOTAL COSTS OF CVDS IN THE U.S., 2015-2030 ($ BILLIONS)
FIGURE # 10 GLOBAL HEALTHCARE EXPENDITURE, 2012-2016 (% OF GDP)
FIGURE # 11 HEALTHCARE EXPENDITURE OF DEVELOPED ECONOMIES, 2016 (% OF THEIR GDP)
FIGURE # 12 HEALTHCARE EXPENDITURE OF DEVELOPING ECONOMIES, 2016(% OF THEIR GDP)
FIGURE # 13 THE GLOBAL CARDIOLOGY DEVICES MARKET BY ANGIOPLASTY, 2017-2023, ($ MILLION)
FIGURE # 14 THE GLOBAL CARDIOLOGY DEVICES MARKET BY CARDIOVASCULAR STENTS, 2017-2023, ($ MILLION)
FIGURE # 15 THE GLOBAL CARDIOLOGY DEVICES MARKET BY CATHETERS, 2017-2023, ($ MILLION)
FIGURE # 16 THE GLOBAL CARDIOLOGY DEVICES MARKET BY CARDIAC RHYTHM MANAGEMENT, 2017-2023, ($ MILLION)
FIGURE # 17 THE GLOBAL CARDIOLOGY DEVICES MARKET BY CARDIOVASCULAR ASSISTIVE DEVICES, 2017-2023, ($ MILLION)
FIGURE # 18 THE GLOBAL CARDIOLOGY DRUGS MARKET BY ANTITHROMBOTIC, 2017-2023, ($ MILLION)
FIGURE # 19 THE GLOBAL CARDIOLOGY DRUGS MARKET BY ANTIDYSLIPIDEMIC, 2017-2023, ($ MILLION)
FIGURE # 20 THE GLOBAL CARDIOLOGY DRUGS MARKET BY ANTIHYPERTENSIVE, 2017-2023, ($ MILLION)
FIGURE # 21 THE GLOBAL CARDIOLOGY DRUGS MARKET BY ANTI-STROKE, 2017-2023, ($ MILLION)
FIGURE # 22 THE GLOBAL CARDIOLOGY DRUGS MARKET BY BETA BLOCKERS, 2017-2023, ($ MILLION)
FIGURE # 23 THE GLOBAL CARDIOLOGY DRUGS MARKET BY BETA AGONISTS, 2017-2023, ($ MILLION)
FIGURE # 24 THE GLOBAL CARDIOLOGY DRUGS MARKET BY ALPHA BLOCKERS, 2017-2023, ($ MILLION)
FIGURE # 25 THE GLOBAL CARDIOLOGY DRUGS MARKET BY ALPHA AGONISTS, 2017-2023, ($ MILLION)
FIGURE # 26 THE GLOBAL CARDIOLOGY DRUGS MARKET BY SODIUM CHANNEL BLOCKERS, 2017-2023, ($ MILLION)
FIGURE # 27 THE GLOBAL CARDIOLOGY DRUGS MARKET BY CALCIUM CHANNEL BLOCKERS, 2017-2023, ($ MILLION)
FIGURE # 28 THE GLOBAL CARDIOLOGY DRUGS MARKET BY VASODILATORS DRUGS, 2017-2023, ($ MILLION)
FIGURE # 29 THE GLOBAL CARDIOLOGY DRUGS MARKET BY RENIN INHIBITORS, 2017-2023, ($ MILLION)
FIGURE # 30 THE GLOBAL CARDIOLOGY DRUGS MARKET BY ANGIOTENSIN RECEPTOR BLOCKERS, 2017-2023, ($ MILLION)
FIGURE # 31 THE GLOBAL CARDIOLOGY DRUGS MARKET BY DIURETICS, 2017-2023, ($ MILLION)
FIGURE # 32 THE GLOBAL CARDIOLOGY DRUGS MARKET BY THROMBOLYTIC, 2017-2023, ($ MILLION)
FIGURE # 33 THE GLOBAL CARDIOLOGY SURGERY MARKET BY CORONARY ARTERY BYPASS GRAFTING, 2017-2023, ($ MILLION)
FIGURE # 34 THE GLOBAL CARDIOLOGY SURGERY MARKET BY TRANSMYOCARDIAL LASER REVASCULARIZATION, 2017-2023, ($ MILLION)
FIGURE # 35 THE GLOBAL CARDIOLOGY SURGERY MARKET BY HEART VALVE, 2017-2023, ($ MILLION)
FIGURE # 36 THE GLOBAL CARDIOLOGY SURGERY MARKET BY CARDIAC ARRHYTHMIA, 2017-2023, ($ MILLION)
FIGURE # 37 THE GLOBAL CARDIOLOGY SURGERY MARKET BY ANEURYSM REPAIR, 2017-2023, ($ MILLION)
FIGURE # 38 THE GLOBAL CARDIOLOGY SURGERY MARKET BY HEART TRANSPLANT, 2017-2023, ($ MILLION)
FIGURE # 39 US CARDIOLOGY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($MILLION)
FIGURE # 40 CANADA CARDIOLOGY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE # 41 UNITED KINGDOM MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE # 42 FRANCE CARDIOLOGY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE # 43 GERMANY CARDIOLOGY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE # 44 ITALY CARDIOLOGY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE # 45 SPAIN CARDIOLOGY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
